TY  - JOUR
TI  - Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients
AV  - public
Y1  - 2016/06//
EP  - 434
N2  - INTRODUCTION: 
CA125 in peritoneal dialysis (PD) effluent dialysate has been used as a surrogate biomarker for the health of the peritoneum in PD patients. However CA125 is synthesised by epithelial cells and as such is not specific for the peritoneum, and most studies have only measured peritoneal CA125, without serum CA125 values. As such we wished to determine the factors which influenced PD effluent CA125 in a large contemporaneous cohort.


METHODS: 
We measured dialysate effluent CA125 in PD patients attending for routine assessment of peritoneal membrane function with a peritoneal equilibration test (PET), with corresponding serum CA125.

RESULTS: 
Serum and dialysate CA125 were measured in 205 PD patients; 59.0 ą 16.8 years, median PD treatment 3 (2?20) months, 59 % male, 42.4 % diabetic, with 31.2 % treated by continuous ambulatory peritoneal dialysis, 22 % by automated overnight peritoneal dialysis cycler (APD) and 46.8 % by APD with a day time exchange. The median serum CA125 was 21 (13?38) U/ml, with an effluent 4 h PD PET effluent of 20 (11.5?36.5) U/ml. PET PD effluent dialysate was associated with PET dialysate total protein (? 12.9, p < 0.001), serum CA125 (? 0.109, p = 0.002), residual renal function (? 0.53, p = 0.018) and age (? 0.145, p = 0.042) and negatively with the number of PD cycles/day (? ?2.19, p = 0.001). There was no association with prior peritonitis episodes.

CONCLUSION: 
PD effluent CA125 concentrations were associated with peritoneal protein losses and increased by the usage of higher glucose dialysates to compensate for loss of residual renal function.
ID  - discovery10053261
PB  - WICHTIG PUBLISHING
KW  - Science & Technology
KW  -  Life Sciences & Biomedicine
KW  -  Urology & Nephrology
KW  -  Cancer Antigen 125
KW  -  Peritoneal Dialysis
KW  -  Glucose
KW  -  Icodextrin
KW  -  Residual Renal Function
KW  -  Dwell Time
KW  -  Extracellular Volume Expansion
KW  -  Cancer Antigen-125
KW  -  Multifrequency Bioimpedance
KW  -  Transport
KW  -  CA-125
KW  -  CAPD
KW  -  Hemodialysis
KW  -  Sclerosis
KW  -  Markers
KW  -  Cells
VL  - 29
SP  - 427
IS  - 3
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
UR  - http://dx.doi.org/10.1007/s40620-015-0250-9
SN  - 1724-6059
JF  - Journal of Nephrology
A1  - Redahan, L
A1  - Davenport, A
ER  -